Repositorio Dspace

Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry

Mostrar el registro sencillo del ítem

dc.contributor.author Iborra, M
dc.contributor.author Botella, B
dc.contributor.author Martin-Arranz, M-D
dc.contributor.author Ceballos, D
dc.contributor.author Martínez-Pascual, C
dc.contributor.author Garrido, A
dc.contributor.author Varela, P
dc.contributor.author Moreta, M
dc.contributor.author Brunet-Mas, Eduard
dc.contributor.author González-Lama, Y
dc.contributor.author Rodríguez-González, E
dc.contributor.author Vicuna, M
dc.contributor.author Gisbert, J-P
dc.contributor.author Ordas, I
dc.contributor.author Arguelles-Arias, F
dc.contributor.author Tosca-Cuquerella, J
dc.contributor.author Vicente-Lidon, R
dc.contributor.author Sierra-Ausin, M
dc.contributor.author Rodríguez-Lago, I
dc.contributor.author Martin-Rodríguez, D
dc.contributor.author Paredes, JM
dc.contributor.author Sicilia, B
dc.contributor.author García-de-la-Filia, I
dc.contributor.author Jiménez, N
dc.contributor.author Barreiro-de-Acosta, M
dc.contributor.author Betore, E
dc.contributor.author Ferrer-Bradley, I
dc.contributor.author García-Alles, L
dc.contributor.author Huguet, JM
dc.contributor.author Castellet-Farrus, S
dc.contributor.author García, M-J
dc.contributor.author Gutiérrez-Casbas, A
dc.contributor.author Ponferrada-Díaz, A
dc.contributor.author Ramos, L
dc.contributor.author Calafat, M
dc.contributor.author Vera, I
dc.contributor.author Suárez-Ferrer, Consuelo
dc.contributor.author Fernández-Velado, E
dc.contributor.author Rodríguez-Sánchez, S
dc.contributor.author Mínguez, A
dc.contributor.author Mancebo, A
dc.contributor.author Barrio, J
dc.contributor.author Lario, S
dc.contributor.author de-La-Cruz, D-R
dc.contributor.author Hernández-Camba, Alejandro
dc.contributor.author Rodríguez-Gutiérrez, C
dc.contributor.author Chaparro, M
dc.contributor.author Ricart, E
dc.contributor.author Almenara-Michelena, L
dc.contributor.author Balaguer, A
dc.contributor.author Domenech, E
dc.contributor.author Nos, P
dc.date.accessioned 2026-08-03T10:28:57Z
dc.date.available 2026-08-03T10:28:57Z
dc.date.issued 2026-05
dc.identifier.issn 2050-6406
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/27194
dc.description.abstract BACKGROUND: Upadacitinib (UPA) is the first oral Janus kinase (JAK) inhibitor approved for the treatment of Crohn's disease (CD). Real-world data, particularly from large nationwide cohorts, remain limited. This study aimed to evaluate the real-world effectiveness, safety, and treatment persistence of UPA in patients with CD. METHODS: Multicenter observational study including patients with CD who received UPA, using data from a nationwide registry. Patients were classified according to active luminal disease, extraintestinal manifestations (EIMs), or combination therapy with another biological therapy. Disease activity was assessed using the Harvey-Bradshaw Index (HBI), C-reactive protein (CRP), and fecal calprotectin (FC) at baseline and weeks 12, 24, and 52. Endoscopic outcomes were evaluated when available. Adverse events (AEs), hospitalizations, and treatment discontinuations were recorded. RESULTS: 300 patients were included, representing a highly treatment-refractory population, with 98% previously exposed to anti-TNF agents and 59% to three or more advanced therapies. In those treated for active luminal disease, corticosteroid-free clinical remission was achieved in 60%-62% of patients at weeks 12, 24 and 52. CRP normalization increased from 64% at week 12%-74% at week 52, while FC normalization improved from 48% to 64%. Patients treated for EIMs achieved high and sustained remission rates with excellent treatment persistence. Early remission at week 12 was strongly associated with sustained remission and meaningful endoscopic improvement. UPA was discontinued in 98 patients (39%). AEs were reported in 71 patients (24%). CONCLUSIONS: In this large real-world cohort, UPA demonstrated sustained clinical and biochemical effectiveness, meaningful endoscopic response, and a safety profile consistent with clinical trial data. Early response emerged as a key predictor of long-term outcomes, supporting the clinical utility of UPA.
dc.language.iso eng
dc.publisher WILEY
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es *
dc.subject.mesh Humans
dc.subject.mesh Female
dc.subject.mesh Male
dc.subject.mesh Crohn Disease/drug therapy/diagnosis
dc.subject.mesh Registries/statistics & numerical data
dc.subject.mesh Adult
dc.subject.mesh Heterocyclic Compounds, 3-Ring/adverse effects/administration & dosage/therapeutic use
dc.subject.mesh Treatment Outcome
dc.subject.mesh Remission Induction/methods
dc.subject.mesh Middle Aged
dc.subject.mesh Janus Kinase Inhibitors/adverse effects/administration & dosage/therapeutic use
dc.subject.mesh C-Reactive Protein/analysis
dc.subject.mesh Leukocyte L1 Antigen Complex/analysis
dc.subject.mesh Young Adult
dc.subject.mesh Feces/chemistry
dc.subject.mesh Severity of Illness Index
dc.title Real-World Effectiveness and Safety of Upadacitinib in Crohn's Disease: Insights From the Eneida Registry
dc.type info:eu-repo/semantics/article 
dc.identifier.pmid 42057704
dc.relation.publisherversion https://onlinelibrary.wiley.com/doi/10.1002/ueg2.70223
dc.type.version info:eu-repo/semantics/publishedVersion 
dc.identifier.doi 10.1002/ueg2.70223
dc.journal.title UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
dc.identifier.essn 2050-6414


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta